Fenton Mary Kay
Insider CIK 1378589 · ACHN SVP and CFO · ONCR Director · CGEM Chief Financial Officer · TALS Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc | A Award | 2026-06-30 | 2026-07-02 | 1,541 | $8.60 | $13.3K | 127,921 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | S Sale | 2026-02-20 | 2026-02-23 | 4,398 | $13.62 | $59.9K | 126,380 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award deriv | 2026-02-18 | 2026-02-19 | 137,500 | — | $0 | 137,500 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award | 2026-02-18 | 2026-02-19 | 68,750 | — | $0 | 130,778 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award | 2025-12-31 | 2026-01-05 | 27 | $6.49 | $175 | 62,028 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award deriv | 2025-02-19 | 2025-02-21 | 120,000 | — | $0 | 120,000 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award | 2025-02-19 | 2025-02-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| CGEM Cullinan Therapeutics, Inc | A Award deriv | 2024-04-29 | 2024-04-30 | 200,000 | — | $0 | 200,000 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | F Tax w/h | 2023-07-03 | 2023-07-06 | 12,946 | $3.08 | $39.9K | 68,054 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | A Award deriv | 2023-02-01 | 2023-02-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | A Award deriv | 2023-02-01 | 2023-02-03 | 150,000 | — | $0 | 150,000 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | A Award | 2022-09-10 | 2022-09-13 | 80,000 | — | $0 | 81,000 | SEC↗ |
| ONCR Oncorus, Inc. | A Award deriv | 2022-06-23 | 2022-06-24 | 12,500 | — | $0 | 12,500 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | A Award deriv | 2022-02-01 | 2022-02-02 | 200,000 | — | $0 | 200,000 | SEC↗ |
| TALS Talaris Therapeutics, Inc. | A Award | 2021-12-31 | 2022-02-02 | 1,000 | $13.00 | $13.0K | 1,000 | SEC↗ |
| ONCR Oncorus, Inc. | A Award deriv | 2021-06-16 | 2021-06-17 | 12,500 | — | $0 | 12,500 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2018-02-09 | 2018-02-13 | 250,000 | — | $0 | 250,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2017-01-17 | 2017-01-19 | 165,000 | — | $0 | 165,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | P Buy | 2016-12-05 | 2016-12-05 | 2,500 | $4.11 | $10.3K | 2,500 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2016-01-20 | 2016-01-22 | 118,000 | — | $0 | 118,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise deriv | 2015-12-28 | 2015-12-30 | 43,500 | — | $0 | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | S Sale | 2015-12-28 | 2015-12-30 | 43,500 | $10.08 | $438.5K | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise | 2015-12-28 | 2015-12-30 | 43,500 | $1.05 | $45.7K | 43,500 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise deriv | 2015-01-23 | 2015-01-23 | 13,125 | — | $0 | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | S Sale | 2015-01-23 | 2015-01-23 | 13,125 | $16.00 | $210.0K | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise | 2015-01-23 | 2015-01-23 | 13,125 | $4.00 | $52.5K | 13,125 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2014-12-02 | 2014-12-04 | 110,000 | — | $0 | 110,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2014-03-04 | 2014-03-06 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2013-12-17 | 2013-12-19 | 250,000 | — | $0 | 250,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | A Award deriv | 2012-12-18 | 2012-12-20 | 145,000 | — | $0 | 145,000 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise deriv | 2012-01-10 | 2012-01-11 | 10,625 | — | $0 | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | S Sale | 2012-01-10 | 2012-01-11 | 10,625 | $12.00 | $127.5K | 0 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | M Exercise | 2012-01-10 | 2012-01-11 | 10,625 | $1.60 | $17.0K | 10,625 | SEC↗ |
| ACHN ACHILLION PHARMACEUTICALS | S Sale | 2012-01-09 | 2012-01-11 | 4,375 | $9.34 | $40.9K | 0 | SEC↗ |